ANVISA Suspends Sinovac Vaccine Trial, Citing Unspecified “Severe Adverse Event”

The trial is one of three large late-stage trials underway for the Sinovac vaccine. The vaccine has, however, faced controversy in Brazil with President Jair Bolsonaro dismissing it as lacking credibility.

RIO DE JANEIRO, BRAZIL - Brazil’s health regulator ANVISA has suspended a clinical trial for China’s Sinovac coronavirus vaccine citing a severe adverse event, surprising the trial organisers who countered there had been a death but it was unrelated to the vaccine.

The national health regulatory agency, ANVISA, said on Monday, November 9th, that the event occurred on October 29th but did not specify if it took place in Brazil or in another country. It also did not give an indication of how long the suspension might last.

The trial is one of three large late-stage trials underway . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?